Autistic People Against Neuroleptic Abuse
This publication is included in the Autistic Autism Scholarship Project. one author of this publication is identified as autistic in the project.
About the autistic author markerMurray, D. (2019). Autistic People Against Neuroleptic Abuse. In Autistic Community and the Neurodiversity Movement (pp. 51-63). Springer Singapore. https://doi.org/10.1007/978-981-13-8437-0_4 · ISBN : 9789811384363 · Place of publication : Singapore
This publication is integrated into AutiHub through:
Authors
Abstract
Abstract In 1998, Dinah Murray founded APANA (Autistic People Against Neuroleptic Abuse), an autistic-led campaign in the UK to stop the overuse of drugs being given to people with intellectual disabilities. The campaign subverted the medicalization of “challenging behavior” and focused on three cases studies of institutionalized autistic adults who were being overprescribed. Murray compiled statistics on their medications and their visits to doctors, found allies, began spreading the message via the internet and using legal recourse. Espousing a non-pathological model of autism, APANA raised awareness of the harms of overmedication in the learning disability world and, perhaps, more caution in the psychiatric world. It may have impacted on some government guidelines, and on the author’s reputation as resourceful and reasonable, which benefitted her future activism.
Bibliography cited by this reference
Cited references are imported from external metadata sources when they are available. The list may be partial.
Cited bibliography overview
These indicators describe the bibliography cited by this publication. An author name is counted each time it appears in one cited reference, so the same person can be counted more than once. Names not yet linked to an author already present in AutiHub are treated as unknown, not as non-autistic. Last computed: 3 Oct 2026 01:00.
- With a DOI
- 12
- Without a DOI, from raw bibliography text
- 5
- References with detected author names
- 12 / 17 (70.6%)
- Without detected author names
- 5
- Without a structured title
- 5
- Without a stable identifier
- 5
- References with raw author names still to review
- 4
- References with external metadata lookup issues
- 0
- From DOI or external metadata
- 27
- From validated raw bibliography text
- 0
- Raw names already validated
- 0
- Raw names still to review
- 7
-
(2006). Catatonia in Autism Spectrum Disorders . Elsevier.OpenAlex
-
Autism Europe. (1998). Draft code of good practice on prevention of violence against persons with autism. Brussels: Autism-Europe.Type: OtherCrossref
-
Lorna Wing , Amitta Shah (2000). Catatonia in autistic spectrum disorders . British Journal of Psychiatry, 176(4), 357-362. Royal College of Psychiatrists.Crossref OpenAlex OpenCitations
-
J. Brylewski , L. Duggan (1999). Review: Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomized controlled trials . Journal of Intellectual Disability Research, 43(5), 360-371. Wiley.Crossref OpenAlex OpenCitations
-
C. Kiernan , D. Reeves , A. Alborz (1995). The use of anti‐psychotic drugs with adults with learning disabilities and challenging behaviour . Journal of Intellectual Disability Research, 39(4), 263-274. Wiley.Crossref OpenAlex OpenCitations
-
R. S. Shiwach , T. J. Carmody (1998). Prolactogenic effects of risperidone in male patients — a preliminary study . Acta Psychiatrica Scandinavica, 98(1), 81-83. Wiley.Crossref OpenAlex OpenCitations
-
D Manchester (1993). Neuroleptics, learning disability, and the community: some history and mystery. BMJ, 307(6897), 184-187. BMJ.Crossref OpenAlex OpenCitations
-
Richard Tranter , David Healy (1998). Neuroleptic discontinuation syndromes . Journal of Psychopharmacology, 12(4), 401-406. SAGE Publications.Crossref OpenAlex OpenCitations
-
D. Branford (1996). Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities . Journal of Intellectual Disability Research, 40(4), 322-329. Wiley.Crossref OpenCitations
-
Helen McConachie , David Mason *Autistic author. Learn more… , Jeremy R. Parr , Deborah Garland , Colin Wilson , Jacqui Rodgers (2018). Enhancing the validity of a quality of life measure for Autistic people . Journal of Autism and Developmental Disorders, 48(5), 1596. Springer Science and Business Media LLC.
-
Richard Ashcroft , Bill Fraser , Michael Kerr , Zahir Ahmed (2001). Are antipsychotic drugs the right treatment for challenging behaviour in learning disability?: The place of a randomised trial . Journal of Medical Ethics, 27(5), 338-343. BMJ.Crossref OpenAlex OpenCitations
-
Murray, D. (1999). ‘Potions, pills and human rights’ in opening volume of Good Autism Practice (long version). http://www.autismusundcomputer.de/potions.en.html .Type: OtherCrossref
-
Melissa DeFilippis , Karen Dineen Wagner (2025). Treatment of Autism Spectrum Disorder in Children and Adolescents . Psychopharmacology Bulletin, 46(2), 18-41. Medworks Media Inc..OpenAlex
-
D. Branford (1996). Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities . Journal of Intellectual Disability Research, 40(4), 322-329. Wiley.OpenAlex
-
Unwin, G., & Deb, S. (2006). Your guide to taking medicine for behaviour problems: Easy read. University of Birmingham. https://www.birmingham.ac.uk/Documents/college-les/psych/ld/LDEasyReadGuide.pdf .Type: OtherCrossref
-
Alexander, R., Branford, D., & Devapriam, J. (2016). Psychotropic drug prescribing for people with intellectual disability, mental health problems and/or behaviours that challenge: Practice guidelines. (Faculty Report No. FR/ID/09). https://www.rcpsych.ac.uk .Type: OtherCrossref
-
M DeFilippis (2016). DeFilippis, M., & Wagner, K. D. (2016). Treatment of autism spectrum disorder in children and adolescents. Psychopharmacology Bulletin, 46(2), 18–41. Psychopharmacology Bulletin, 46(2), 18.Type: OtherCrossref